IP Library › Granted Patent US 8,119,767
Granted Patent B2
US 8,119,767 · App. 11/624,132 · Granted Feb 21, 2012

Post-translational modifications and clostridial neurotoxins

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,119,767
App. No.
11/624,132
Granted
Feb 21, 2012
Kind
B2
Abstract

The present invention discloses modified neurotoxins with altered biological persistence. In one embodiment, the modified neurotoxins are derived from Clostridial botulinum toxins. Such modified neurotoxins may be employed in treating various conditions, including but not limited to muscular disorders, hyperhidrosis, and pain.

Claims (3)

1. A modified botulinum neurotoxin type E comprising a botulinum neurotoxin type E including an amino acid modification of a tyrosine phosphorylation site,

wherein the tyrosine phosphorylation site is SEQ ID NO: 46,

wherein the amino acid modification decreases biological persistence of the modified botulinum neurotoxin relative to a naturally-occurring botulinum neurotoxin type E without the amino acid modification.